Abstract: A concentrated adjuvant composition comprises an incompletely hydrated water-soluble polymer suspended in a liquid medium, a suspension agent and a hydration inhibitor component.

Abstract: Provided are an antibacterial liquid having excellent sedimentation resistance, an antibacterial film formed using the antibacterial liquid, and a wet wipe produced using the antibacterial liquid. The antibacterial liquid is an antibacterial liquid including antibacterial microparticles, a binder, and a solvent, in which the antibacterial microparticles contain a silver-supporting inorganic oxide, the average particle size of the antibacterial microparticles is 1.0 ?m or less, the binder includes at least one silane compound, the solvent includes an alcohol and water, and the content of the alcohol with respect to the total mass of the antibacterial liquid is 10% by mass or more.

Abstract: The present invention relates to an ultra-thin film silk fibroin/collagen composite implant for tissue engineering and a manufacturing method therefor. The ultra-thin film silk fibroin/collagen silk fibroin/collagen composite implant according to the present invention has no cytotoxicity and can minimize the influence on cell growth, due to the combined use of a refined silk fibroin aqueous solution, collagen and various biomaterials, and thus can be widely used as an ultra-thin film implant for implanting.

Abstract: The present invention relates to quaternary ammonium disinfecting cleaning compositions comprising a quaternary ammonium compound, an alkyl a polyglycoside with a CMC greater than 1000 ppm and a chelant. Beneficially, the compositions provide residual sanitizing efficacy without diminished performance and without scale formation when diluted with hard water. The compositions are suitable for inactivating and/or reducing infectious agents, particularly Norovirus, Adenovirus, and Polyomavirus.

Abstract: A storage stable L-menthol composition including a tablet, caplet, capsule, or sachet dosage form has therein a core containing crystalline L-menthol and at least one pharmaceutical excipient. A proteinaceous coating of a continuous film of proteinaceous material is over the core. The film is effective to substantially prevent the crystalline L-menthol from volatilizing and leaving the core when stored at a temperature of 40 degrees C. and 75% relative humidity from between 1 day to 30 days. The dosage form contains an effective amount of the crystalline L-menthol for treating a gastrointestinal disorder.

Abstract: Drug delivery using bio-affecting drugs, particularly with shape changing drug delivery devices. Embodiments are included for depots for delivery of a therapeutic agent that change from an elongated state ex vivo to a coil in vivo where the agent is released.

Abstract: A pet food composition specifically formulated for a small dog can include a combination of specific antioxidants, amino acids, metabolism components, and bone health components to maintain health. Methods of maintaining health and modulating select health parameters are also provided.

Abstract: A method for the production of freeze-dried pellets comprising factor VIII comprises the steps of: a) freezing droplets of a solution comprising factor VIII to form pellets; b) freeze-drying the pellets; wherein in step a) the droplets are formed by means of droplet formation of the solution comprising factor VIII into a cooling tower which has a temperature-controllable inner wall surface and an interior temperature below the freezing temperature of the solution and wherein in step b) the pellets are freeze-dried in a rotating receptacle which is housed inside a vacuum chamber.

Abstract: The present invention discloses a hair conditioner composition comprising a) from about 0.15% to about 16% moisture control material or mixtures of moisture control materials wherein one or more moisture control material is selected from the group containing: i. Class I Moisture Control Material having the structure selected from: wherein R? is —COOY, sulfonic acid, or —C?CH—COOY, Y is hydrogen or a metal ion, R1, R2, R3, R4, R5 is hydrogen, methyl, ethyl, propyl, vinyl, allyl, methoxy, ethoxy, hydroxyl, halogen, sulfate, sulfonate, nitro, or —CH?CH—COOR, and wherein the moisture control material is an acidic material and further wherein the moisture control material has a % Protein binding higher than 20 and Molecular Volume lower than 500 and Partition coefficient octanol to water (log P) lower than 3 and hydrogen binding higher than 10 and pKa lower than 5.0; ii.

Abstract: A powder dispersant includes an ester compound of a polyglycerol having an average degree of polymerization of the polyglycerol, calculated from its hydroxyl value, in the range 2 to 20, a monovalent carboxylic acid or at least one derivative thereof, and a divalent carboxylic acid or at least one derivative thereof.

Abstract: An oral disintegrating tablet which contains rosuvastatin or a salt thereof and is stable to light is provided. An oral disintegrating tablet stable to light, temperature and humidity can be provided by preparing a multi-layered tablet containing rosuvastatin or a pharmaceutically acceptable salt thereof as an active ingredient, a light stabilizer, and an inorganic salt or a basic oxide.

Abstract: Suggested is a pharmaceutical composition comprising valerian extracts or their derivatives that is particularly useful for affecting the sebaceous gland metabolism by exerting a relevant activity as regulator of sebum production (sebogenesis) and the subcutis adipocytes metabolism by regulating adipogenesis.

Abstract: Compositions including an aqueous phase emulsified within an external fatty phase comprising at least one silicone are provided. The compositions include iron oxide having a silane-treated surface, zinc-oxide having a silane-treated surface, a titanium dioxide-silica composite particulate, and hollow spheres of acrylic polymer.

Abstract: Pharmaceutical combinations comprise stable complexes with controlled particle size, increased apparent solubility and increased dissolution rate comprising as active compound Ivacaftor and Lumacaftor, their salts, or derivatives thereof, which are useful in the treatment of cystic fibrosis transmembrane conductance regulator (CFTR) mediated disease. More specifically, the pharmaceutical composition comprising the complexes possesses instantaneous redispersibility, increased apparent solubility and permeability, no observable food effect which deliver the opportunity of precise dosing and ease of administration of the reconstituted complex in solution form. Further disclosed are methods of formulating and manufacturing the complexes, pharmaceutical compositions containing the complexes, and methods of treatment using the complexes and their pharmaceutical compositions.

Abstract: Cosmetic compositions (e.g., foundation, primer, eye shadow or other skin composition) capable of forming a multilayer structure after application to a keratinous material are provided, as well as methods of using same. Certain compositions comprise at least two immiscible components: Component A which comprises about 0.01% to 60% by weight with respect to the total weight of the composition of at least one silicone- and/or hydrocarbon-containing film forming agent having at least one glass transition temperature lower than normal human body temperature; and Component B which comprises about 0.01% to 90% by weight with respect to the total weight of the composition of one or more silicone compounds in amounts sufficient to achieve a viscosity of about 1,000 cSt to 2,000,000 cSt, wherein the weight ratio of the silicone- and/or hydrocarbon-containing film forming agent(s) in Component A to silicone compound(s) in Component B is from about 1:50 to 1.5:1.

Abstract: The present invention relates to the development of a targeted delivery system for the oral delivery of probiotics or therapeutic agent for various indications, including and not 5 limited to active and prophylaxis treatment of Clostridium difficile infection, antibiotic associated diarrhea, irritable bowel syndrome, Crohn's disease, intestinal flora replacement, supplemental flora treatments for patients taking antibiotics, and for restoration of balance and signaling between the intestinal microbiome and the intestinal cells in patients under treatment of metabolic syndrome manifestations, specifically 10 diabetes, insulin resistance, obesity, hyperlipidemia and hypertension. The present invention restores altered probiotic organism imbalances that are characteristic of said diseases among others as well as defines a platform technology development for site specific delivery of probiotic organisms in the GI tract of a 15 mammal, most specifically the ileum and/or right colon of a human subject.

Abstract: A patch includes an adhesive layer and a release liner laminated on at least one surface of a backing. The adhesive layer comprises, as an adhesive base agent, at least one selected from the group consisting of acrylate-based adhesives and rubber-based adhesives, and the adhesive layer comprises 0.3 to 5% by mass of a nonfunctional silicone oil having a kinematic viscosity of 10 to 350 cSt at 25° C.

Abstract: A pharmaceutical or cosmetic carrier for topical administration substantially consists of phosphatidylcholine, monoglyceride, fatty acid ester of C1-C3 alcohol; volatile solvent selected from ethanol and its combinations with C3-C4 alcohol and/or volatile silicone oil. Also disclosed are pharmaceutical and cosmetic compositions comprising the carrier and pharmaceutically or cosmetically active agent(s).

Abstract: Described herein are soft capsules and enteric soft capsules comprising cationic Type A gelatin and acid insoluble enteric polymers. In particular, the compositions and methods for manufacturing all-natural enteric soft capsules comprising Type A gelatin and matrix fills are described. In one embodiment, the enteric soft capsules comprise active ingredients such as non-steroidal anti-inflammatory drugs (NSAIDs). In another embodiment, the enteric soft capsule comprises matrix fills of omega-3 fatty acids.

Abstract: Anhydrous antiperspirant composition in aerosol form comprising an antiperspirant active agent and a water-insoluble film-forming block ethylenic polymer The present invention relates to an anhydrous composition in aerosol form containing: i) an oily phase comprising, in a physiologically acceptable medium: —at least one volatile oil, and —one or more antiperspirant active agents chosen from aluminum and/or zirconium salts, and —one or more water-insoluble film-forming block ethylenic polymers comprising a first block with a glass transition temperature (Tg) of greater than or equal to 85° C. and a second block with a Tg of less than or equal to 20° C., and ii) one or more propellants; the said oily phase containing less than 15% by weight and even more preferably less than 12% by weight of non-volatile polydimethylsiloxane relative to the total weight of the oils.